In conclusion, our data suggest that RIG‐I expression is essential for the effectiveness of IFN‐α and anti‐PD‐1 combination therapy, offering potential clinical benefits in CRC treatment (Figure 6h). Here, IFNA1 is linked to colorectal carcinoma.